Mabion SA 2021 AR2
The report outlines Mabion S.A.'s operational and financial performance for the fiscal year 2021. A key milestone was the successful technology transfer and commercial manufacturing agreement with Novavax, Inc. for the Nuvaxovid COVID-19 vaccine antigen, which generated the company's first sales revenues of PLN 56.9 million and a net profit of PLN 1.9 million. Mabion also regained full commercialization rights for its biosimilar MabionCD20 following the termination of its agreement with Mylan. Additionally, the company maintained its Integrated Management System, certified under ISO 14001, ISO 45001, and ISO 50001 standards, and continued its commitment to equal opportunities and environmental protection.
Company: Mabion SA
Sector: Manufacturing
Country: Poland
Year: 2021
Type: AR2
Pages: 84
Back to company
Mabion SA
Directors' Report
The report outlines Mabion S.A.'s operational and financial performance for the fiscal year 2021. A key milestone was the successful technology transfer and commercial manufacturing agreement with Novavax, Inc. for the Nuvaxovid COVID-19 vaccine antigen, which generated the company's first sales revenues of PLN 56.9 million and a net profit of PLN 1.9 million. Mabion also regained full commercialization rights for its biosimilar MabionCD20 following the termination of its agreement with Mylan. Additionally, the company maintained its Integrated Management System, certified under ISO 14001, ISO 45001, and ISO 50001 standards, and continued its commitment to equal opportunities and environmental protection.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees